Advancements in Dengue Fever Treatment: Insights from Island Pharmaceuticals CEO

In a recent interview with Proactive, Island Pharmaceuticals CEO Dr. David Foster shared exciting updates regarding the company's ongoing efforts to develop a potential treatment for dengue fever. Dr. Foster elaborated on the significant progress made with ISLA-101, the company's drug candidate, emphasizing the promising results obtained from a recent single ascending dose study. Specifically, he highlighted the highly encouraging pharmacokinetics (PK) data collected from this study, which involved 24 subjects. These findings are instrumental in providing critical insights into how ISLA-101 interacts within the body, laying the foundation for establishing appropriate dosing regimens for the upcoming Phase 2a clinical trial. Notably, the PK data indicates that even after a single dose administration, ISLA-101 achieves blood concentrations known to be effective against dengue fever infections. Dr. Foster underscored the significance of these findings, stressing the urgent need for effective treatment options for dengue fever, a disease that annually affects approximately 400 million individuals and remains endemic in around 100 countries worldwide.